<DOC>
	<DOCNO>NCT02232230</DOCNO>
	<brief_summary>Radiation combination Provenge base immunotherapy may improve outcome see image well immunologic monitoring . This study assess effect radiation therapy augment anti-tumor response immune therapy Provenge .</brief_summary>
	<brief_title>A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are Receive Combination Radiation Sipuleucel-T</brief_title>
	<detailed_description>It common knowledge host make anti-tumor immune response , although often ineffective cause tumor regression . Boosting responses immunotherapy therefore attractive , relatively benign adjunctive cancer treatment . Little known regard standard anti-cancer therapy like radiation therapy might interact immunotherapy clinical setting . We interested know tumor cell death occasion radiation therapy might augment anti-tumor response immune therapy , Provenge . The tentative assumption cell death follow radiation therapy stimulate anti-tumor immunity , could provide permanent solution cure cancer discourage tumor spread throughout body . In order find assumption correct , patient undergo radiation 28 day prior Provenge , highly develop , laboratory analysis tumor-specific immunity imaging perform .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subjects recruit population patient castrate refractory metastatic prostate cancer ( mCRPC ) make decision treat radiation therapy one metastatic site concern follow least 28 day later Provenge . The potential subject unwilling hesitant participate reason and/or fails complete appropriate Informed Consent Form .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>